IMA-950 is under clinical development by Immatics and currently in Phase I for Astrocytoma. According to GlobalData, Phase I drugs for Astrocytoma have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IMA-950’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

IMA-950 overview

IMA-950 is under development for the treatment of relapsing glioblastoma, glioma including astrocytoma, oligoastrocytoma or oligodendroglioma and low grade glioma. The vaccine candidate is administered intradermally, and subcutaneously. It is a multi-peptide cancer vaccine containing 11 tumor-associated peptides. It consists of different synthetic tumor-associated peptides (TUMAPs). TUMAPs are dissolved in water and administered together with an adjuvant. These TUMAPs are derived from antigens overexpressed on tumor cells. The therapeutic candidate is developed using XPRESIDENT technology. It was also under development for the intradermal  treatment of glioblastoma multiforme (GBM).

Immatics overview

Immatics is a biopharmaceutical company focused on the development of T cell immunotherapies to fight against cancer. The company is headquartered in Tubingen, Baden-Wurttemberg, Germany.

For a complete picture of IMA-950’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.